Ethnic differences in nifedipine pharmacokinetics and pharmacodynamics: Comparison of Middle Eastern Arabs with other populations

Saudi Pharmaceutical Journal

Volumn 6, Issue 3-4, 1998, Pages 217-227

  Abou Auda, Hisham S ^a   Najjar, Tawfeeg A ^a   Al Fawzan, Nasser F ^b   Gilzai, Naushad M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

Ethnic differences; Nifedipine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

NIFEDIPINE;

ADULT; ARAB; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; CAUCASIAN; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; ETHNOLOGY; HEART RATE; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RACE DIFFERENCE;

EID: 0031796983     PISSN: 13190164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Stone P, Antam E, Muller J and Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Haemodynamic effects and clinical applications. Ant Int Med 1980; 93: 886-904.
2. Sorkin EM, Clissold SP and Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1985; 30: 182-274.
3. Nebert DW, Adesnik M, Coon MJ, Estabrook BW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF and Kemper B, et al. The P-450 gene superfamily: recommended nomenclature. DNA 1987; 6: 1-11.
4. Gonzalez FJ. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40: 243-288.
5. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT and Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987; 80: 1029-1036.
6. Guengerich FP. Oxidative cleavage of carboxylic acid esters by cytochrome P-450. J Biol Chem 1987; 262: 8459-8462.
7. Guengerich FP, Peterson LA and Bocker RH. Cytochrome P-450-catalyzed hydoxlation and carboxylic acid ester cleavage of Hantzsch pyridine esters. J Biol Chem 1988; 263: 8176-8183.
8. Wood AJJ and Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20(5):350-373.
9. Islam SI, Idle JR and Smith RL. The polymorphic 4-hydroxylation of debrisoquin in a Saudi Arab population. Xenobiotica 1980; 10:819-825.
10. Mahgoub A, Idle JR and Smith RL. A population and familial study of the defective and alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 1979; 9: 51-56.
11. Lou YC, Bertilsson L and Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in native Chinese population. Lancet 1987; 2: 852-853.
12. Nakamura K, Goto F, Ray WA, McAllister CB and Jacqz E. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
13. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE and Breimer DD. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33:3721-3724.
14. Schellens JHM, Soons PA and Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy volunteers. Biochem Pharmacol 1988; 37: 2507-2510.
15. Renwick AG, Robertson DRC, Macklin BS, Challenor V, Waller DG and George CF. The pharmacokinetics of oral nifedipine - a population study. Br J Clin Pharmac 1988; 25:701-708.
16. Hoyo-Vadillo C, Castaneda-Hernandez, Herrera JE, Vidal-Garate J, Moreno-Ramos A, Chavez F and Hong E. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: Further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29:816-820
17. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG and George CF. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmac 1991; 31:399-403
18. Castaneda G, Hoyo-Vadillo C, Palma-Aguirre JA and Flores-Murrieta FJ. Pharmacokinetics of oral nifedipine in different population. J Clin Pharmacol 1992; 32:140-145.
19. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF and Amanullah M. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54:329-338.
20. Sowunmi A, Rashid TJ, Akinyinka OO and Renwick AG., Ethnic differences in nifedipine kinetics: comparison between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995; 40:489-493.
21. El-Sayed YM, Niazi EM and Khidr SH. High-performance liquid chromatographic method for the determination of nifedipine in plasma and its use in pharmacokinetic studies. J Clin Pharm Ther 1993; 18:325-330.
22. Debbas NMG, Jackson SHD and Turner P. A comparison of the haemodynamic effects of nifedipine, nisoldipine and nitrendipine in man. Eur J Clin Pharmacol 1986; 30:393-397.
23. Tateishi T, Ohashi K, Sudo T, Sakamoto K, Toyosaki N, Hosoda S, Toyo-oka T, Kumagai Y, Sugimoto K, Fujimura A and Ebihara A. Dose dependent effect of diltiazem on the pharmacokinetics of nifedipine. J Clin Pharmacol 1989; 29:994-997.
24. Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, Vidal-Garate J, Salazar LA, Moreno-Ramos A, Chavez F, Tena I and Hong E. Pharmacokinetics of oral nifedipine: relevance of the distribution phase. J Clin Pharmacol 1989; 29: 251-256.
25. Ramsch KD and Sommer JS. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5(suppl II): 18-24.
26. Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG and George DF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-58.
27. Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ and Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35:742-749.